Advertisement

Research on Chemical Intermediates

, Volume 45, Issue 2, pp 471–486 | Cite as

Molecular docking, synthesis and anticonvulsant activity of some novel 3-(2-substituted)-4-oxothiazolidine-3-yl)-2-phenylquinazoline-4(3H)-ones

  • Sampada S. JangamEmail author
  • Sagar B. Wankhede
  • Sohan S. Chitlange
Article
  • 39 Downloads

Abstract

As the therapeutic potential of quinazolinone and thiazolidinone is well mentioned in literature for their versatile biological activities, their related toxicological profiles cannot be ignored. So, the purpose of this study is to synthesize 3-(2-substituted)-4-oxothiazolidine-3-yl)-2-phenylquinazoline-4(3H)-ones (3a3k) and evaluate them as anticonvulsant agents. Novel series of 3a3k were synthesized and their structures elucidated on the basis of elemental and spectral analyses. A hybrid scaffold containing quinazolinone and thiazolidinone moieties was synthesized to get the title compounds, and their in vivo anticonvulsant activities were performed by maximal electro-shock (MES) induced convulsion model at a dose of 25 mg/kg body weight. Six compounds, 3b, 3c, 3d, 3e, 3f and 3i, were found to have significant anticonvulsant activities with their durations of tonic hind limb extension ranging from 13.117 to 16.450 s and animal protection from 83 to 100%. The results were compared with the standard. All compounds exhibited good binding energies ranging from − 5.15 to − 6.13 kcal/mol with sodium channel IIA inactivation gate (PDB ID: 1BYY) in molecular docking study; amongst them, 3d has shown significant binding energy of − 6.13 kcal/mol. The obtained result showed that biologically active compounds could be used as a template for future design, optimization and investigation for producing more active analogs.

Keywords

Synthesis 4-oxothiazolidine Quinazoline-4(3H)-ones Epilepsy Anticonvulsant activity Molecular docking 

Notes

Acknowledgement

The authors are grateful to the Head, Central Instrumentation Facility (CIF) department, Savitribai Phule Pune University, Pune, India for providing the facilities for Spectral Analysis of compounds.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    C. Wei, D. Wu, Z. Sun, K. Chai, Z. Quan, Med. Chem. Res. 19, 925 (2009)CrossRefGoogle Scholar
  2. 2.
    M. Gasior, R. Carter, S. Goldberg, J. Witkin, J. Pharrmacol. Exp. Ther. 282, 543 (1997)Google Scholar
  3. 3.
    V. Alagarsamy, S. Govindaraj, Med. Chem. Res. 22, 1711 (2013)CrossRefGoogle Scholar
  4. 4.
    G. Bell, J. Sander, Seizure 10, 306 (2002)CrossRefGoogle Scholar
  5. 5.
    A. Seth, P. Sharma, A. Tripathi, P. Choubey, P. Srivastava, P. Tripathi, S. Shrivastava, Med. Chem. Res. 27, 1206 (2018)CrossRefGoogle Scholar
  6. 6.
    A. EI-Helby, R. Ayyad, H. Sakr, A. Abdelrahim, K. EI-Adl, F. Sherbiny, I. Eissa, M. Khalifa, J. Mol. Struct. 1130, 333 (2017)CrossRefGoogle Scholar
  7. 7.
    Z. Quan, C. Zhang, C. Yang, X. Deng, Med. Chem. Res. 21, 3294 (2012)CrossRefGoogle Scholar
  8. 8.
    B. Spear, Epilepsia 42, 31 (2001)CrossRefGoogle Scholar
  9. 9.
    H. Bootsma, L. Ricker, Y. Hekster, J. Hulsman, D. Lambrechts, M. Majoie, A. Schellekens, M. de Krom, A. Aldenkamp, Seizure 18, 327 (2009)CrossRefGoogle Scholar
  10. 10.
    G. Kennedy, S. Lhatoo, CNS Drugs 22, 739 (2008)CrossRefGoogle Scholar
  11. 11.
    S. Xue, J. McKenna, W. Shieh, O. Repic, J. Org. Chem. 69, 6474 (2004)CrossRefGoogle Scholar
  12. 12.
    D. Al-Shamary, M. Al-Alshaikh, N. Kheder, Y. Mabkhot, S. Badshah, Chem. Cent. J. 11, 1 (2017)CrossRefGoogle Scholar
  13. 13.
    M. Al-Alshaikh, D. Al-Shammary, F. El-Baih, Res. J. Chem. Environ. 17, 48 (2013)Google Scholar
  14. 14.
    A. Alafeefy, A. Kadi, A. El-Azab, S. Abdel-Hamid, M. Daba, Arch. Pharm. (Weinheim) 341, 377 (2008)CrossRefGoogle Scholar
  15. 15.
    V. Ram, B. Farhanullah, A.Srivastava Tripathi, Bioorg. Med. Chem. 11, 2439 (2003)CrossRefGoogle Scholar
  16. 16.
    A. Al-Obaid, S. Abdel-Hamide, H. El-Kashef, A. Abdel-Aziz, A. El-Azab, H. Al-Khamees, H. El-Subbagh, Eur. J. Med. Chem. 44, 2379 (2009)CrossRefGoogle Scholar
  17. 17.
    L. Werbel, M. Degnan, J. Med. Chem. 30, 2151 (1987)CrossRefGoogle Scholar
  18. 18.
    Y. Kabri, N. Azas, A. Dumetre, Eur. J. Med. Chem. 45, 616 (2010)CrossRefGoogle Scholar
  19. 19.
    Y. Kim, H. Choi, J. Lee, Bioorg. Med. Chem. Lett. 18, 6279 (2008)CrossRefGoogle Scholar
  20. 20.
    S. Kashaw, V. Jatav, P. Mishra, N. Jain, J. Stable, Eur. J. Med. Chem. 44, 4335 (2009)CrossRefGoogle Scholar
  21. 21.
    V. Jatav, P. Mishra, S. Kahaw, J. Stable, Eur. J. Med. Chem. 43, 1945 (2008)CrossRefGoogle Scholar
  22. 22.
    A. El-Azab, E. Tahir, Bioorg. Med. Chem. Lett. 22, 1879 (2012)CrossRefGoogle Scholar
  23. 23.
    K. Babaoglu, M. Page, V. Jones, M. McNeil, C. Dong, J. Naismith, R. Lee, Bioorg. Med. Chem. Lett. 13, 3227 (2003)CrossRefGoogle Scholar
  24. 24.
    V. Gududuru, E. Hurh, J. Dalton, D. Miller, J. Med. Chem. 48, 2584 (2005)CrossRefGoogle Scholar
  25. 25.
    M. Vigorita, R. Ottana, F. Monforte, R. Maccari, A. Traovato, Bioorg. Med. Chem. Lett. 11, 2791 (2001)CrossRefGoogle Scholar
  26. 26.
    B. Goel, R. Tyagi, E. Bansal, N. Sinha, Eur. J. Med. Chem. 34, 265 (1999)CrossRefGoogle Scholar
  27. 27.
    N. Desai, A. Dodiya, A. Makwana, Med. Chem. Res. 21, 2320 (2012)CrossRefGoogle Scholar
  28. 28.
    A. Errington, T. Stohr, G. Lees, Curr. Top. Med. Chem. 5, 15 (2005)CrossRefGoogle Scholar
  29. 29.
    I. Batool, A. Saeed, I. Qureshi, S. Kalsoom, A. Razzaq, Res. Chem. Intermed. 42, 1139 (2016)CrossRefGoogle Scholar
  30. 30.
    C. Rohl, F. Boeckman, C. Baker, T. Scheuer, W. Catterall, R. Klevit, Biochemical 38, 855 (1999)CrossRefGoogle Scholar
  31. 31.
    M. Sharma, S. Suthar, V. Aggarwal, M. Chauhan, A. Sharma, S. Bansal, Med. Chem. Res. 24, 1331 (2015)CrossRefGoogle Scholar
  32. 32.
    G. Morris, R. Huey, W. Lindstrom, M. Sanner, R. Belew, D. Goodsell, A. Olson, J. Comput. Chem. 30, 2785 (2009)CrossRefGoogle Scholar
  33. 33.
    S. Bansal, B. Sinha, R. Khosa, Med. Chem. Res. 22, 134 (2013)CrossRefGoogle Scholar
  34. 34.
    P. Goodford, J. Med. Chem. 28, 849 (1985)CrossRefGoogle Scholar
  35. 35.
    S. Allison, R. Bacquet, J. McCammon, Biopolymers 27, 251 (1998)CrossRefGoogle Scholar
  36. 36.
    K. Sharp, R. Fine, B. Honig, Science 236, 1460 (1987)CrossRefGoogle Scholar
  37. 37.
    F. Solis, R.J.-B. Wets, Math. Oper. Res. 6, 19 (1981)CrossRefGoogle Scholar
  38. 38.
    A. Joseph, S. Suthar, V. Jaiswal, S. Lohan, S. Bansal, A. Chaudhary, A. Tiwari, A. Alex, Eur. J. Med. Chem. 63, 589 (2013)CrossRefGoogle Scholar
  39. 39.
    C. Kavitha, S. Basappa, K. Swamy, S. Mantelingu, M. Doreswamy, J. Sridar, K.Rangappa Prasad, Bioorg. Med. Chem. 14, 2290 (2006)CrossRefGoogle Scholar
  40. 40.
    C. Lipinski, F. Lombardo, B. Dominy, P. Feeney, Adv. Drug Deliv. Rev. 46, 3 (2001)CrossRefGoogle Scholar
  41. 41.
    R. Sharma, G. Misra, J. Sainy, S. Chaturvedi, Med. Chem. Res. 20, 245 (2011)CrossRefGoogle Scholar
  42. 42.
    E. LaVoie, G. Patani, Chem. Rev. 96, 3147 (1996)CrossRefGoogle Scholar
  43. 43.
    H. Erlenmeyer, M. Leo, Helv. Chim. Acta 15, 1171 (1932)CrossRefGoogle Scholar
  44. 44.
    H. Bolcskei, I. Tamawa, P. Kocsis, Med. Chem. Res. 17, 356 (2008)CrossRefGoogle Scholar
  45. 45.
    C. Kuo, Mol. Pharmacol. 54, 712 (1998)Google Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • Sampada S. Jangam
    • 1
    Email author
  • Sagar B. Wankhede
    • 1
  • Sohan S. Chitlange
    • 1
  1. 1.Dr. D. Y. Patil Institute of Pharmaceutical Sciences and ResearchPimpri, PuneIndia

Personalised recommendations